{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"The proportion of patients achieving progressive disease, stable disease, partial response, very good partial response, complete response, stringent complete response for best-achieved response, using the IMWG criteria for assessing response, at any time during pembrolizumab therapy will be reported.","groups":[{"description":"Participants received pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Treatment (Pembrolizumab)"}],"populationDescription":"Data not collected","reportingStatus":"POSTED","timeFrame":"Approximately 1 year and 8 months","title":"Proportion of Participants by Best Achieved Response Rate","type":"SECONDARY"}